May 2026Real-world biomarker testing rates, targeted therapy use, and clinical outcomes in patients with advanced gastric or GEJ cancer in the United StatesPrecision medicineGastric cancer
May 2026Using ML to predict rapid progression for patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with frontline (1L) CDK 4/6 inhibitors (CDK 4/6i)Precision medicineBreast cancerArtificial intelligence
May 2026External validation of a deep learning CT biomarker to predict first-line immune checkpoint inhibitor monotherapy-associated survival in PD-L1–high metastatic non–small cell lung cancerPrecision medicineArtificial intelligenceLung cancer
May 2026Real-world post-progression outcomes following 1L ribociclib + aromatase inhibitor (AI) versus Al alone in African American and low socio-economic status patients with HR+/HER2- mBC in USPrecision medicineHealth equityBreast cancer
February 2026A feasibility analysis to align fit-for-purpose real-world data to emulate the AZUR-1single-arm clinical trial in patients with dMMR/MSI-H locally advanced rectal cancerPrecision medicineColorectal cancerRegulatory
August 2025A novel predictive gene signature for liver metastasis (LM) in NSCLC using a comprehensive linked Clinical-Molecular DatabasePrecision medicineLung cancer
April 2025Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer typesPrecision medicineReal-World Data